RETRACTED: Gravina et al. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models. Cancers 2019, 11, 1604

The journal retracts the article, “The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models” [1], cited above.

Following publication, concerns were brought to the attention of the Editorial Office regarding the duplication or partial overlap between a sub-image in Figure 6 [1] and sub-images in Figure 5 in another publication [2] with partially overlapping authorship.

Adhering to our standard procedure, an investigation was conducted by the Editorial Office and the Editorial Board that confirmed two partial overlaps and one duplication between Figure 6 in this publication [1] and sub-figures included in Figure 6 in another paper [2]. While the authors provided replacement images during the investigation, the Editorial Board found the explanations regarding the duplicated data insufficient to warrant a correction. Consequently, the Editorial Board has lost confidence in the reliability of the findings and decided to retract this publication [1], as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30).

This retraction was approved by the Editor-in-Chief of the Cancers journal.

The authors did not provide a comment on this decision.

The corresponding author, Claudio Festuccia, takes full responsibility for the concerns raised and clarifies that the other co-authors were not directly involved in the duplication of the figures in question.